Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management. (28th February 2019)

• Record Type: Journal Article
• Authors: Girmenia, Corrado; Busca, Alessandro; Candoni, Anna; Cesaro, Simone; Luppi, Mario; Nosari, Anna Maria; Pagano, Livio; Rossi, Giuseppe; Venditti, Adriano; Aversa, Franco
• Is Part Of: Medical mycology. Volume 57(2019)Supplement 2
• Page Start: S127
• Page End: S137
• Publication Date: 2019-02-28
• Subjects: breakthrough fungal infections -- antifungal prophylaxis -- acute myeloid leukemia -- triazoles; Medical mycology -- Periodicals; Veterinary mycology -- Periodicals; Mycology -- Periodicals; Mycoses -- Periodicals; Pathogenic fungi -- Periodicals; 616.969005
• DOI: 10.1093/mmy/myy091
• Languages: English
• ISSNs: 1369-3786

Abstract

Abstract: In the attempt to establish definitions and provide shared approaches to breakthrough invasive fungal diseases (br-IFD) in acute myeloid leukemia (AML) patients submitted to intensive chemotherapy and receiving triazoles as mould active primary antifungal prophylaxis (MA-PAP), literature on br-IFD in AML patients receiving triazoles MA-PAP was reviewed and a Consensus Development Conference Project was convened. The following four candidate key-questions were generated and formed the set of questions of the present document: "definition of br-IFD, " "diagnostic strategy during MA-PAP to detect br-IFD, " "possible causes of MA-PAP failure, " "management of br-IFD."